MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406818 | Name: ST2825

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ST-2825 is MyD88 inhibitor. ST2825 provides neuroprotection after experimental traumatic brain injury in mice. ST2825 significantly inhibited the proliferation of and promoted the apoptosis of HCC cells. Moreover, ST2825 significantly decreased bcl-2 expression, increased cleaved caspase-3 expression (P < 0.05), and reduced p65 nuclear expression (P < 0.05) in a dose-dependent manner. ST2825 inhibits the proliferation of and promotes the apoptosis of HCC cells, thereby suggesting that ST2825 may be a new drug for HCC treatment.

Chemical Structure

ST2825
CAS#894787-30-5

Theoretical Analysis

MedKoo Cat#: 406818

Name: ST2825

CAS#: 894787-30-5

Chemical Formula: C27H28Cl2N4O5S

Exact Mass: 590.1157

Molecular Weight: 591.50

Elemental Analysis: C, 54.83; H, 4.77; Cl, 11.99; N, 9.47; O, 13.52; S, 5.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
894787-30-5
Synonym
ST-2825; ST 2825; ST2825.
IUPAC/Chemical Name
(2R,4'R,8a'R)-1-(2-(4-(2-(2,4-dichlorophenoxy)acetamido)phenyl)acetyl)-6'-oxotetrahydro-2'H,6'H-spiro[pyrrolidine-2,7'-pyrrolo[2,1-b][1,3]thiazine]-4'-carboxamide
InChi Key
HBLHLJXFIPCEMW-ZJSFPPFMSA-N
InChi Code
InChI=1S/C27H28Cl2N4O5S/c28-17-4-7-21(19(29)13-17)38-15-22(34)31-18-5-2-16(3-6-18)12-23(35)32-10-1-9-27(32)14-24-33(26(27)37)20(25(30)36)8-11-39-24/h2-7,13,20,24H,1,8-12,14-15H2,(H2,30,36)(H,31,34)/t20-,24-,27-/m1/s1
SMILES Code
O=C([C@@H]1N2[C@](C[C@@]3(N(C(CC4=CC=C(NC(COC5=CC=C(Cl)C=C5Cl)=O)C=C4)=O)CCC3)C2=O)([H])SCC1)N
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 591.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Qi M, Yin L, Xu L, Tao X, Qi Y, Han X, Wang C, Xu Y, Sun H, Liu K, Peng J. Dioscin alleviates lipopolysaccharide-induced inflammatory kidney injury via the microRNA let-7i/TLR4/MyD88 signaling pathway. Pharmacol Res. 2016 Jul 16;111:509-522. doi: 10.1016/j.phrs.2016.07.016. [Epub ahead of print] PubMed PMID: 27431331. 2: Zhang HS, Li H, Zhang DD, Yan HY, Zhang ZH, Zhou CH, Ye ZN, Chen Q, Jiang TW, Liu JP, Hang CH. Inhibition of myeloid differentiation factor 88(MyD88) by ST2825 provides neuroprotection after experimental traumatic brain injury in mice. Brain Res. 2016 Jul 15;1643:130-9. doi: 10.1016/j.brainres.2016.05.003. Epub 2016 May 4. PubMed PMID: 27155455. 3: Yao H, Hu C, Yin L, Tao X, Xu L, Qi Y, Han X, Xu Y, Zhao Y, Wang C, Peng J. Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway. Int Immunopharmacol. 2016 Jul;36:132-41. doi: 10.1016/j.intimp.2016.04.023. Epub 2016 Apr 29. PubMed PMID: 27135544. 4: He WT, Zhang LM, Li C, Li SY, Ding ZC, Fang ZM, Meng FY, Chen ZK, Zhou P. Short-term MyD88 inhibition ameliorates cardiac graft rejection and promotes donor-specific hyporesponsiveness of skin grafts in mice. Transpl Int. 2016 Aug;29(8):941-52. doi: 10.1111/tri.12789. Epub 2016 Jun 14. PubMed PMID: 27125343. 5: Deng Y, Sun J, Zhang LD. Effect of ST2825 on the proliferation and apoptosis of human hepatocellular carcinoma cells. Genet Mol Res. 2016 Mar 4;15(1):15016826. doi: 10.4238/gmr.15016826. PubMed PMID: 26985932. 6: Liu M, Xu Y, Han X, Yin L, Xu L, Qi Y, Zhao Y, Liu K, Peng J. Dioscin alleviates alcoholic liver fibrosis by attenuating hepatic stellate cell activation via the TLR4/MyD88/NF-κB signaling pathway. Sci Rep. 2015 Dec 10;5:18038. doi: 10.1038/srep18038. PubMed PMID: 26655640; PubMed Central PMCID: PMC4674875. 7: Feng Z, Wang Z, Yang M, Zhou L, Bao Y. Polysaccharopeptide exerts immunoregulatory effects via MyD88-dependent signaling pathway. Int J Biol Macromol. 2016 Jan;82:201-7. doi: 10.1016/j.ijbiomac.2015.11.002. Epub 2015 Nov 4. PubMed PMID: 26546866. 8: Qi M, Zheng L, Qi Y, Han X, Xu Y, Xu L, Yin L, Wang C, Zhao Y, Sun H, Liu K, Peng J. Dioscin attenuates renal ischemia/reperfusion injury by inhibiting the TLR4/MyD88 signaling pathway via up-regulation of HSP70. Pharmacol Res. 2015 Oct;100:341-52. doi: 10.1016/j.phrs.2015.08.025. Epub 2015 Sep 5. PubMed PMID: 26348276. 9: Li J, Wang X, Zhang F, Yin H. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacol Ther. 2013 Jun;138(3):441-51. doi: 10.1016/j.pharmthera.2013.03.003. Epub 2013 Mar 24. Review. PubMed PMID: 23531543; PubMed Central PMCID: PMC3686650. 10: Loiarro M, Ruggiero V, Sette C. Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MyD88 inhibitors. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):222-6. doi: 10.1016/j.clml.2013.02.003. Epub 2013 Mar 13. Review. PubMed PMID: 23490990. 11: Capolunghi F, Rosado MM, Cascioli S, Girolami E, Bordasco S, Vivarelli M, Ruggiero B, Cortis E, Insalaco A, Fantò N, Gallo G, Nucera E, Loiarro M, Sette C, De Santis R, Carsetti R, Ruggiero V. Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology (Oxford). 2010 Dec;49(12):2281-9. doi: 10.1093/rheumatology/keq226. Epub 2010 Aug 25. PubMed PMID: 20739362. 12: Van Tassell BW, Seropian IM, Toldo S, Salloum FN, Smithson L, Varma A, Hoke NN, Gelwix C, Chau V, Abbate A. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. J Cardiovasc Pharmacol. 2010 Apr;55(4):385-90. doi: 10.1097/FJC.0b013e3181d3da24. Erratum in: J Cardiovasc Pharmacol. 2011 Feb;57(2):272. Dosage error in article text. PubMed PMID: 20125030. 13: Loiarro M, Capolunghi F, Fantò N, Gallo G, Campo S, Arseni B, Carsetti R, Carminati P, De Santis R, Ruggiero V, Sette C. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007 Oct;82(4):801-10. Epub 2007 Jun 4. PubMed PMID: 17548806.

View History

Leukoefdin

Leukoefdin